February 04, 2013 at 14:22 PM EST
UPDATE 1-Gilead's two hepatitis C drug trials meet study goals
Feb 4 (Reuters) - Biotechnology company Gilead Sciences on Monday said two trials of its hepatitis C drug, the centerpiece of its oral hepatitis C treatment program, met their goals in two late-stage studies.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here